Core Viewpoint - Enlivex Therapeutics reported significant profitability in 2025, primarily driven by the appreciation of its treasury assets linked to decentralized prediction markets, particularly through the RAIN token Financial Performance - Enlivex generated a net income of $1.23 billion for the full year 2025, with diluted earnings per share (EPS) of $25.48, calculated in accordance with GAAP [3][7] - The company ended 2025 with $2.31 billion in total treasury and treasury-related assets and $1.93 billion in shareholders' equity, attributed to market-based revaluation of these assets [2][4] Treasury Strategy - The company has adopted a "dual-engine" strategy combining clinical-stage drug development with a digital-asset treasury focused on decentralized prediction markets [4] - Enlivex is building a digital-asset treasury around the RAIN token, holding an exclusive option to buy up to 275 billion RAIN at $0.0033 per token, with a planned purchase of 3 billion RAIN for $10 million [6][11] - The treasury strategy is centered on RAIN, which is viewed as a decentralized protocol with increasing trading volumes and institutional engagement [8][9] Clinical Development - Enlivex's lead product, Allocetra, has received FDA clearance for a Phase IIb trial in knee osteoarthritis, with expected topline data in 2027 [5][14] - The company emphasizes the clinical platform's importance for long-term value, with Allocetra showing meaningful improvements in pain and function for osteoarthritis patients [13][15] Market Position and Future Outlook - Management noted that the market capitalization is currently trading at a discount to its treasury valuation, which they hope to address through growth in the prediction market ecosystem [16] - Enlivex aims to potentially self-fund its clinical development through a small percentage of treasury asset appreciation, allowing investors to benefit from both clinical and treasury sides [17][19]

Financial Data and Key Metrics Changes - For the full year 2025, the company reported a net income of $1.23 billion and diluted earnings per share of $25.48, reflecting a significant appreciation in treasury and treasury-related assets [3][11] - The total treasury and treasury-related assets reached $2.31 billion, with shareholders' equity at $1.93 billion, indicating strong financial positioning [11][12] Business Line Data and Key Metrics Changes - The company's dual-engine model integrates clinical development with a treasury strategy focused on prediction markets, which is expected to drive long-term value [3][10] - The clinical platform, particularly Allocetra, has shown statistically significant results and a favorable safety profile, with a clear pathway toward late-stage development in osteoarthritis [9][16] Market Data and Key Metrics Changes - The prediction markets ecosystem is experiencing structural momentum, with increasing trading volumes and institutional engagement, positioning the company to capture early opportunities [12][18] - The RAIN token, as a primary digital treasury reserve asset, is expected to benefit from the growing decentralized prediction markets, enhancing long-term shareholder value [13][15] Company Strategy and Development Direction - The company aims to establish itself as a leader in a new category of public companies that combine scientific innovation with emerging financial infrastructure [10][18] - A strategic partnership with the Rain Foundation allows the company to acquire RAIN tokens at a fixed price, enhancing its capital structure and growth potential [5][8] Management's Comments on Operating Environment and Future Outlook - Management believes that the prediction markets will continue to evolve into a core layer of global financial infrastructure, validating the company's treasury strategy [4][12] - The company is optimistic about the scalability of its dual-engine model, driven by the growth of both prediction markets and its clinical programs [30][31] Other Important Information - The company announced a $21 million debt financing agreement to fund clinical development and acquire additional RAIN tokens at a discount [6][7] - A share repurchase program was approved to acquire up to $20 million of outstanding shares, reflecting confidence in the company's long-term value [8] Q&A Session Summary Question: Why is Enlivex posting large profits for 2025 despite a downturn in crypto? - The company's exposure to prediction markets, particularly the RAIN token, has led to significant valuation increases, contrasting with broader crypto market trends [20][22] Question: How to explain the market cap discount to treasury valuation? - The current market sentiment towards crypto has led to net asset value discounts, but there is hope for recovery as the prediction market ecosystem grows [23] Question: Does this change how clinical-stage companies can be financed? - The funding landscape for early-stage biotech has become more challenging, but Enlivex's model allows for self-funding through treasury asset appreciation, mitigating dilution concerns [24][25] Question: Is this a one-off outcome for prediction markets in public company earnings? - Management views this as the beginning of a broader shift towards integrating prediction markets into public company structures [26] Question: How should investors view Enlivex after these results? - Investors are likely to reassess the company's value proposition, recognizing the potential of its dual model strategy [29] Question: What are the key drivers for scaling this model? - The scalability will depend on the growth of the prediction markets ecosystem and the success of the clinical programs, with several milestones planned for the next two years [30]

Core Viewpoint - Enlivex Ltd. has successfully completed a $21 million debt financing agreement, which will support its operational plans and acquisition of RAIN tokens, while also implementing a share repurchase program to enhance shareholder value [1][2][3][6]. Group 1: Debt Financing - Enlivex secured a $21 million debt financing agreement with The Lind Partners, resulting in net proceeds of approximately $18.7 million after offering expenses [1][4]. - The note from the financing is convertible into Enlivex's ordinary shares at a fixed price of $2.69175 per share, representing a 264% premium to the Nasdaq closing price on March 20, 2026 [1][6]. Group 2: Acquisition of RAIN Tokens - The company exercised an option to acquire 3,030,303,030 RAIN tokens at a price of $0.0033 per token, which is a 62% discount to its closing price on March 22, 2026, totaling an aggregate purchase amount of $10 million [2][6]. - The duration of the option to acquire an additional 272,121,212,121 RAIN tokens at the same price has been extended from November 30, 2026, to December 31, 2027 [2][6]. Group 3: Share Repurchase Program - The Board of Directors approved a share repurchase program allowing the company to buy back up to $20 million of its outstanding ordinary shares, subject to regulatory requirements [2][6]. - The repurchase may occur through various means, including open market transactions and privately negotiated transactions, with no obligation to purchase any shares [2][6]. Group 4: Company Overview - Enlivex is a quality longevity company focused on advancing Allocetra™, an advanced clinical-stage immunotherapy targeting age-related inflammatory conditions, particularly osteoarthritis [5][7]. - The company operates a prediction markets treasury strategy based on the RAIN protocol, integrating the development of therapeutics with exposure to the prediction markets ecosystem [7].

Core Viewpoint - The listing of the RAIN token on the Kraken cryptocurrency exchange is expected to enhance liquidity and accessibility for participants in the RAIN ecosystem, contributing to improved price discovery and secondary market trading [1][3]. Group 1: Company Overview - Enlivex Therapeutics Ltd. is focused on the late-stage clinical development of Allocetra™, a novel therapy for osteoarthritis, and has adopted a treasury strategy centered on the RAIN token [4]. - RAIN serves as the governance and utility token for a decentralized predictions and options protocol built on the Arbitrum network, allowing users to create and trade markets tied to real-world events [3]. Group 2: Market Context - Kraken, the second-largest U.S.-based cryptocurrency exchange, supports a wide range of digital assets and had a total trading volume exceeding $2 trillion in 2025, making it a significant platform for secondary market trading [2]. - The exchange is known for its strong security, regulatory compliance, and transparency, attracting institutional and professional market participants [2]. Group 3: Clinical Development Focus - Osteoarthritis affects over 32.5 million Americans and more than 300 million individuals globally, with projections indicating that 78 million Americans will have the condition by 2040 [5]. - The burden of osteoarthritis is substantial, leading to over one million hospitalizations annually in the U.S., primarily for total joint replacement, highlighting the critical need for effective treatments [5].

Core Viewpoint - Enlivex Therapeutics has successfully listed its primary treasury asset, the RAIN token, on the WhiteBIT cryptocurrency exchange, enhancing market access and liquidity for the token [1][2]. Group 1: Company Overview - Enlivex Therapeutics is a clinical stage company focused on macrophage reprogramming immunotherapy, particularly in the late-stage clinical development of Allocetra™, aimed at treating osteoarthritis [4]. - The company has developed a treasury strategy centered on RAIN, which serves as its primary treasury reserve asset, providing investors with exposure to digital capital [4]. Group 2: RAIN Token and Market Strategy - The RAIN token is the governance and utility token of a decentralized predictions and options protocol on the Arbitrum network, allowing users to create and trade markets tied to real-world events [3]. - The listing of RAIN on WhiteBIT, the largest European cryptocurrency exchange by traffic, is expected to broaden regional market access and enhance secondary market liquidity, supporting the development of market infrastructure for Enlivex's digital asset strategy [2]. Group 3: Osteoarthritis Market Context - Osteoarthritis affects over 32.5 million Americans and more than 300 million individuals globally, with projections indicating that 78 million Americans will have the condition by 2040 [5]. - The burden of osteoarthritis is significant, leading to over one million hospitalizations annually in the U.S., primarily for total joint replacement, highlighting the critical need for effective treatments [5].

Core Viewpoint - Enlivex Therapeutics Ltd. has announced its decision to voluntarily delist its ordinary shares from the Tel Aviv Stock Exchange (TASE) to focus on U.S.-based trading and reduce administrative costs associated with dual listing [1][4]. Group 1: Delisting Process - The last trading day for the ordinary shares on the TASE is expected to be April 23, 2026, with delisting anticipated around April 26, 2026 [2]. - Shareholders will continue to trade ordinary shares on the TASE until the final trading day [2]. - The ordinary shares will continue to be traded on the Nasdaq Capital Market under the symbol "ENLV" [3]. Group 2: Strategic Objectives - The Board of Directors approved the delisting to operate under a single set of listing requirements, which aims to reduce duplicative administrative costs and potentially enhance liquidity on Nasdaq [4]. - The transition allows the company to concentrate its investor and public relations efforts on the U.S. capital markets [4]. Group 3: Company Overview - Enlivex is a clinical-stage biotech company focused on macrophage reprogramming immunotherapy, particularly in the late-stage clinical development of Allocetra™, a therapy for osteoarthritis [5]. - Osteoarthritis affects over 32.5 million Americans and is projected to impact 78 million by 2040, highlighting a significant market need for effective treatments [6].

Group 1 - Enlivex Therapeutics Ltd. reported the listing of its treasury asset, the RAIN token, on the KuCoin cryptocurrency exchange, effective January 6, which is expected to enhance global market access and liquidity for the token [1] - The company has launched a digital asset treasury strategy focused on acquiring RAIN tokens, which serve as the governance and utility token for a decentralized predictions-and-options protocol on the Arbitrum network [2] - Enlivex plans to utilize proceeds from a private investment in public equity of 212 million shares at $1.00 per share to implement the RAIN prediction markets token treasury strategy while maintaining focus on core business operations [3] Group 2 - HC Wainwright highlighted the potential growth trajectory of the RAIN token, referencing precedent cases like Polymarket and Kalshi, which reached an $11 billion valuation, indicating a promising future for prediction markets [4] - If prediction markets achieve $1 trillion in annual volume within five years and RAIN captures a 5% market share, approximately $1.25 billion of RAIN tokens would be purchased and burned in that year alone, with additional tokens burned from cumulative trading volume [5] - These dynamics are expected to significantly reduce token supply, increase daily trading activity, and exert upward pressure on the RAIN token price, leading to an updated price forecast from $7 to $13 by HC Wainwright [6] Group 3 - The update on Enlivex's valuation reflects dilution from the recent PIPE transaction and incorporates the value of RAIN tokens on the balance sheet, along with an updated valuation of the company's Allocetra clinical programs in osteoarthritis [7] - As of the last check, ENLV stock is up 4.52% at $0.93 [7]

Core Viewpoint - Enlivex Therapeutics has successfully listed its primary digital treasury asset, the RAIN token, on the KuCoin cryptocurrency exchange, enhancing market access and liquidity for the token [1][2]. Group 1: Company Overview - Enlivex Therapeutics is the first publicly-listed company to develop a treasury strategy centered on the RAIN token, which serves as its primary treasury reserve asset [4]. - The company is also engaged in the late-stage clinical development of Allocetra™, a novel therapy for osteoarthritis, a condition affecting over 32.5 million Americans and more than 300 million people globally [5]. Group 2: RAIN Token and Digital Asset Strategy - The RAIN token is the governance and utility token of a decentralized predictions and options protocol built on the Arbitrum network, allowing users to create and trade markets tied to real-world events [3]. - The listing of RAIN on KuCoin is expected to significantly enhance global market access and secondary liquidity for Enlivex's digital asset treasury [2][3]. Group 3: KuCoin Exchange - KuCoin is a leading global cryptocurrency exchange with over 40 million users, primarily in Southeast Asia, and ranks among the top ten cryptocurrency exchanges worldwide [2]. - The exchange offers a comprehensive suite of trading products, including spot trading, derivatives, and yield services, which will benefit the trading of RAIN [2].

Market Overview - Bitcoin (BTC) rebounded to nearly $90,000, reversing a previous drop and trading largely unchanged over 24 hours, consistent with slight gains in S&P 500 and Nasdaq futures [1] - The broader market, including CoinDesk 20 (CD20) and CoinDesk 80 (CD80) indexes, showed little change, with RAIN token being a notable winner, adding over 6% [1] Market Sentiment and Catalysts - Market sentiment is currently fearful, as indicated by the Crypto Fear & Greed Index, which has flipped the pain trade higher [3] - The market is awaiting several catalysts this week, including U.S. retail sales, jobs data, inflation reports, and multiple Federal Reserve speakers, which could influence interest rate expectations [2] - Any upside surprise in economic data could reinforce a 'hawkish cut' narrative, while softer data might reopen opportunities for risk assets [3] Volatility and Technical Indicators - The MOVE index indicates renewed bullishness or increased turbulence in the bond market, suggesting that market swoons often accompany heightened volatility [4] - Technical indicators for Nasdaq suggest an end to the recovery rally from November, while BTC's options market shows a bias for puts across multiple timeframes [4] Bitcoin Network and Regulatory News - BTC's hash rate fell by 8% to 1,200 EH/s, attributed to the closure of mining farms in Xinjiang, China [5] - The U.S. Securities and Exchange Commission released a wallet and custody investor guide, highlighting risks associated with different custody models and best practices for investors [5] Traditional Markets - In traditional markets, gold extended its gains, while some analysts caution that the downside for the Dollar Index appears limited [6]

Core Insights - Enlivex Therapeutics Ltd. will host a virtual fireside chat on December 11, 2025, to discuss its recent $212 million private placement and future plans [1][2][3] - The company is focusing on advancing the clinical development of Allocetra™, a therapy for osteoarthritis, which affects over 32.5 million Americans and 300 million people globally [5] Company Plans - Shai Novik, Executive Chairman, will provide updates on the digital asset treasury strategy centered around RAIN token accumulation [2] - Enlivex aims to offer investors exposure to RAIN as a primary treasury reserve asset [4] Clinical Development - Allocetra™ is designed to treat osteoarthritis, a prevalent joint disease with significant hospitalization rates in the U.S. [5] - There are currently no FDA or EMA approved medications that can halt or reverse joint damage in osteoarthritis patients [5]